bispecific antibodies in the treatment pipeline for myeloma in the uk
Published 2 weeks ago • 49 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
4:26
what are bispecific antibodies?
-
3:16
end stage multiple myeloma
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
5:06
bispecific antibodies: late side effects
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
1:17
the promise of bispecific antibodies in the treatment of nhl
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
2:12
risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
4:26
antibodies in multiple myeloma and their impact on treatment
-
1:19
infectious toxicities in patients with multiple myeloma treated with bispecific antibodies